Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trialsNicola A. Hanania, John G. Matthews, Phillip E. Korenblat et al.|The Lancet Respiratory Medicine|2016Cited by 465
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cellsChie Nishioka, Akihito Yokoyama|Leukemia|2008Cited by 86
Downregulation of miR‐217 correlates with resistance of ph<sup>+</sup> leukemia cells to <scp>ABL</scp> tyrosine kinase inhibitorsChie Nishioka, Akihito Yokoyama|Cancer Science|2013Cited by 60
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelinKota Iwahori, Tetsuji Naka, Tadashi Osaki et al.|Lung Cancer|2008Cited by 50
Expression of p‐JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemiaTakayuki Ikezoe, Akihito Yokoyama|International Journal of Cancer|2011Cited by 47